Abstract: The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from thienopyrimidine and thienopyridine compounds Formula I? and Formula II?: where R1, R3, B, Z, Q, p, q and X are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

Abstract: The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula I: wherein R1, R2, R3, B, Z, G, Q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

Abstract: The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from aminoquinoline and aminoquinazoline compounds of Formula I?: where R1, R2, R3, B, Z, Q, p, q and X are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

Abstract: The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from compounds of Formula I?: Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

Abstract: The invention is directed to thienopyrimidines and thienopyridines compounds of Formula I and Formula II: where R1, R3, B, Z, Q, p, q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3, the use of such compounds to reduce or inhibit kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

Abstract: The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from aminopyrimidine compounds of Formula I?: where R3, B, Z, r and R1 are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

Abstract: The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from aminopyrimidine compounds of Formula I?: where R3, B, Z, Q, p, q and R1 are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

Abstract: The invention is directed to aminopyrimidine compounds of Formula I: where R3, B, Z, Q, p, q and R1 are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

Abstract: This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to hetero isonipecotic amides that are potent modulators of VR1 which are useful for the treatment and prevention of disease conditions in mammals.

Abstract: The present invention relates to thienopyrmidine compounds of formula (I) (one of A1 and A2 is S and the other is CH), salts thereof, as well as use and preparation of the same. These compounds are inhibitors of various protein tyrosine kinases (PTKs) of the ErbB family and consequently are useful in the treatment of disorders mediated by aberrant activity of such kinases.

Abstract: A master-receiver in a subscriber television network receives service instances and entitlement information from a headend of the subscriber television network and re-transmits service instances to a client-receiver after dynamic encryption scheme determination.

Abstract: Systems and methods are disclosed for providing downstream signals to a plurality of receiver networks. A receiver network (i.e., a networked multimedia system) includes a splitter/isolation module (SIM), a primary set-top terminal (STT), and at least one remote device. The remote devices communicate with the primary STT via the SIM over coaxial cable. Accordingly, the remote devices utilize some or all of the features including hardware and software that are included in the primary STT via the networked multimedia system.

Abstract: Systems and methods are disclosed for providing downstream signals to a plurality of receiver networks. A receiver network (i.e., a networked multimedia system) includes a splitter/isolation module (SIM), a primary set-top terminal (STT), and at least one remote device. The remote devices communicate with the primary STT via the SIM over coaxial cable. Accordingly, the remote devices utilize some or all of the features including hardware and software that are included in the primary STT via the networked multimedia system. A network guide is provided that displays the past and present activity status of each of the receiving devices.

Abstract: A system that maps media content information to an interactive program guide displayed on a screen includes, among other things, a memory with logic, and a processor configured with the logic to display at least one personal video recording display channel in the interactive program guide. The processor is further preferably configured with the logic to display media content instance listings in the personal video recording display channel for corresponding media content instance recordings.

Abstract: Systems and methods are disclosed for providing objects to a remote digital home communication terminal (remote DHCT) via a gateway device located at a customer premises. One such method, among others, includes receiving a message from a remote DHCT requesting a carousel object, receiving the carousel object from a server device, and transmitting the carousel object to the remote DHCT.

Abstract: A method for providing an interactive program guide (IPG) includes receiving from a user a request for an IPG, and providing the user with an IPG that includes listings that were received by a digital home communication terminal (DHCT) via a subscriber television network, as well as other listings that were not received by the DHCT via the subscriber television network.

Abstract: A server in a subscriber television network receives service instances from a headend of the subscriber television network. The server is adapted to encrypt according to an encryption scheme and re-transmit service instances to a client-receiver. The server reformats the service instance from a first format into a second format the client-receiver can access the service instance.

Abstract: A master-receiver in a subscriber television network receives service instances and entitlement information from a headend of the subscriber television network and re-transmits service instances to a client-receiver after dynamic encryption scheme determination.

Abstract: A method for exporting data includes receiving a request for exporting DHCT-related data and then exporting the DHCT-related data from a digital home communication terminal (DHCT) to a client device, wherein the DHCT and the client device are located at a customer premises.

Abstract: A master device interactively distributes a television signal to a remote device for remote display with low latency between a user input and a television signal change.